Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry
Japanese Journal of Clinical Oncology · 2025
DOI: 10.1093/jjco/hyaf024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Hiroya Kondo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Chondrosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: National Cancer Center Research and Development Funds.
Abstract (Originalsprache)
Background
Chondrosarcoma (CS) is a rare malignant bone tumor exhibiting diverse histological features and clinical behaviors. This study aimed to investigate the epidemiological characteristics, clinical features, prognostic factors, and subtype-specific differences of CS in Japan using National Cancer Registry data.
Methods
We analyzed data from CS cases diagnosed between 2016 and 2019, calculating age-adjusted incidence, estimating overall survival, and identifying prognostic factors through multivariate analysis.
Results
The study identified 1015 CS cases with an age-adjusted incidence of 0.159 per 100 000 population and a mean overall survival of 1205.2 days. Multivariate analysis revealed that female sex, younger age (15–39 years), histological subtypes other than dedifferentiated CS, localized disease, and surgical treatment were associated with better prognoses. Conversely, male sex, older age (≥75 years), dedifferentiated subtype, advanced stage, and non-surgical treatment were linked to a higher risk of death. Significant differences in sex distribution, age at diagnosis, tumor location, disease stage, and tumor differentiation were observed among CS subtypes.
Conclusion
This comprehensive analysis provides valuable insights into CS epidemiology, prognostic factors, and subtype-specific characteristics in Japan. The identification of high-risk groups emphasizes the need for improved therapeutic strategies and supportive care. The observed heterogeneity among CS subtypes underscores the importance of individualized management approaches in treating this complex malignancy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Musculoskeletal Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo, Japan.
- Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, East, 6-5-1 Kashiwanoha, Kashiwa-shi, Chiba, Japan.
- Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tsukiji, Chuo-ku, Tokyo, Japan.
ORCID-Profile: Chigusa Morizane, Shintaro Iwata, Toshiyuki Takemori, Eisuke Kobayashi, Takahiro Higashi
Förderung
- National Cancer Center Research and Development Funds
Zitieren
APA
Kondo, H., Ogura, K., Morizane, C., Satake, T., Iwata, S., Toda, Y., Muramatsu, S., Takemori, T., Kobayashi, E., Higashi, T., & Kawai, A. (2025). Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyaf024
Vancouver
Kondo H, Ogura K, Morizane C, Satake T, Iwata S, Toda Y, et al. Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyaf024
BibTeX
@article{Kondo2025,
author = {Kondo, Hiroya and Ogura, Koichi and Morizane, Chigusa and Satake, Tomoyuki and Iwata, Shintaro and Toda, Yu and Muramatsu, Shudai and Takemori, Toshiyuki and Kobayashi, Eisuke and Higashi, Takahiro and Kawai, Akira},
title = {Chondrosarcoma in Japan: an analytic study using population-based National Cancer Registry},
journal = {Japanese Journal of Clinical Oncology},
year = {2025},
doi = {10.1093/jjco/hyaf024}
}
EUVIMED